TOGETHER
AGAINST RHEUMATOID ARTHRITIS.

We are committed to attacking inflammatory diseases like rheumatoid arthritis (RA). But we’re not alone. We problem-solve across our global offices in 35 countries. We collaborate with external partners to develop innovative therapeutic approaches, and we aim to further advance the care of patients.

FINDING ANSWERS TOGETHER

INTERNAL BIOMARKER
PROGRAM

We appreciate the complexities of inflammatory diseases and the difficulty healthcare professionals and patients face every day. Our internal biomarker program is helping us better understand what drives response to help improve outcomes for patients.

GILEAD AND
GALAPAGOS

In 2015, Gilead entered into a global partnership with Galapagos. In 2019, we further solidified our partnership with a 10-year, global research and development collaboration. Using Galapagos’ unique platform, we’re utilizing disease-related, human primary cell-based assays to discover and verify novel drug targets.

EXPLORING THE MICROBIOME

In 2020, Gilead entered into a multiyear collaboration agreement with Second Genome, a leader in microbiome science. The collaboration seeks to harness the latest insights from the microbiome to identify biomarkers related to the clinical response of investigational compounds.1

GILEAD’S BACKGROUND IN INFLAMMATION.

Gilead logo

1987

Gilead Sciences founded

Gilead building

1999

Gilead establishes international infrastructure as a global company

Spleen tyrosine kinase (SYK) inhibition

2010

Gilead research efforts expand, evaluating spleen tyrosine kinase inhibition and exploring treatments for inflammatory diseases

Gilead scientist evaluating Bruton’s tyrosine kinase (BTK) inhibitors

2014

Gilead and ONO partner to evaluate Bruton’s tyrosine kinase (BTK) inhibitors for B-cell malignancies and inflammatory diseases2

Galapagos building

2015

Gilead and Galapagos announce global collaboration to address inflammatory diseases3

Gilead CEO and Galapagos CEO shaking hands

2019

Gilead and Galapagos embark on a 10-year collaboration to discover and develop transformative therapies in inflammatory diseases4

White pills

2019

27 drugs approved globally to date for patients across multiple disease areas5

Dr in Lab

2020

Gilead enters the microbiome space in a collaboration with Second Genome to discover new biomarkers for inflammatory diseases1

References

References: 1. Data on file. Gilead Sciences, Inc.; 2020. 2. Data on file, Gilead Sciences, Inc.; 2014. 3. Data on file, Gilead Sciences, Inc.; 2015. 4. Data on file, Gilead Sciences, Inc.; 2019. 5. Gilead Life Sciences. https://www.gilead.com/science-and-medicine/medicines. Accessed September 23, 2019.

GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies.
© 2020 Gilead Sciences, Inc. All rights reserved.
UNBP5552 07/20